Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates improved tumor targeting using novel probes in renal cell carcinoma, suggesting enhanced diagnostic potential.
High Resolution Image Download MS PowerPoint Slide Carbonic anhydrase IX (CAIX), a zinc-containing metalloenzyme, is markedly overexpressed in clear cell renal cell carcinoma (ccRCC), making it a promising and vital target for the diagnosis and therapy of this malignancy. In the present study, we synthesized a novel CAIX dimeric probe (CAIX-BC) by coupling two CAIX monomeric moieties (CAIX-DC) via a DOTA chelating scaffold. A head-to-head comparison was subsequently performed between CAIX-BC and the parent CAIX-DC, focusing on their pharmaceutical properties, in vitro cellular binding/uptake characteristics, and in vivo biological behaviors. After decay correction, the radiochemical labeling yield of CAIX-BC reached 77.48 ± 3.36% ( n = 5) at 15 min postradiolabeling, with a radiochemical purity of ≥99%. Furthermore, CAIX-BC exhibited favorable stability both in vitro and in vivo. Notably, the enhanced hydrophilicity of CAIX-BC facilitated its rapid diffusion and elimination from the bloodstream, which is a desirable pharmacokinetic property for nuclear medicine probes. PET/CT imaging was performed in OS-RC-2 tumor-bearing nude mice. The probe exhibited significant accumulation in OS-RC-2 tumors, with a prolonged retention time compared with its monomeric counterpart CAIX-DC. Biodistribution studies further confirmed these imaging results. In conclusion, CAIX-BC is a novel CAIX-targeted probe that holds promise for the detection of ccRCC.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: